31 January 2023 : Clinical Research
A Retrospective Study to Evaluate the Association Between the Glasgow Prognostic Score and Atrial Fibrillation, Stroke, and Mortality at 30 Days and at 1 Year After Coronary Artery Bypass Graft Surgery
Esra Dönmez
1ABCDEF*, Sevgi Özcan 1ABCDEF, Bülent Mert 2BCD, Berk Özkaynak 2ABDF, Sevil Tuğrul 1ABC, İrfan Şahin 1ABDEF, Ertuğrul Okuyan 1AEF
DOI: 10.12659/MSM.939283
Med Sci Monit 2023; 29:e939283
Table 1 Comparison of demographic and laboratory parameters and outcomes of groups with regard to postoperative atrial fibrillation development.
| Variables | All (n=712) | POAF (−) (n=591) | POAF (+) (n=121) | p |
|---|---|---|---|---|
| Age (years) | 60.3±9.7 | 59.6±9.8 | 63.3±8.7 | |
| Male, n (%) | 539 (75.7) | 457 (84.8) | 82 (15.2) | |
| Body Mass Index | 27.9±4.4 | 27.8±4.4 | 27.9±4.5 | 0.735 |
| Hypertension, n (%) | 372 (52.2) | 299 (50.6) | 73 (60.3) | 0.051 |
| Chronic obstructive pulmonary disease, n (%) | 135 (19) | 105 (17.8) | 30 (24.8) | 0.074 |
| Peripherial Artery Disease, n (%) | 53 (7.4) | 40 (6.8) | 13 (10.7) | 0.133 |
| Carotid artery disease, n (%) | 59 (8.3) | 26 (4.4) | 33 (27.3) | |
| Coronary artery disease, n (%) | 189 (26.5) | 160 (27.2) | 29 (24.2) | 0.492 |
| Diabetes mellitus, n (%) | 295 (41.4) | 238 (40.3) | 57 (47.1) | 0.169 |
| Hyperlipidemia, n (%) | 354 (49.7) | 301 (50.9) | 53 (43.8) | 0.153 |
| Cerebrovascular accident, n (%) | 25 (3.5) | 22 (3.7) | 3 (2.5) | 0.785 |
| Smoking, n (%) | 344 (48.3) | 289 (48.9) | 55 (45.5) | 0.051 |
| NYHA III–IV, n (%) | 183 (25.7) | 154 (26.3) | 29 (23.9) | 0.597 |
| EuroSCORE-II | 1.96±1.25 | 1.89±1.13 | 2.27±1.68 | |
| Preoperative treatment, n (%) | ||||
| Statins | 367 (51.5) | 313 (53) | 52 (43) | 0.07 |
| β-blockers | 226 (31.7) | 184 (31.7) | 42 (34.7) | 0.492 |
| ACEI/ARB | 347 (48.7) | 301 (51.2) | 46 (38.6) | |
| Creatinine, (mg/dl) | 0.9±0.3 | 0.8±0.4 | 1.1±0.3 | 0.439 |
| TSH, (mU/L) | 2.5±1.8 | 2.8±1.6 | 1.7±1.0 | 0.069 |
| HbA1c (%) | 6.7±1.8 | 6.7±1.8 | 6.7±1.6 | 0.970 |
| White blood cell, 10/μl) | 7.9±1.7 | 8.1±0.8 | 7.7±1.5 | 0.805 |
| Preoperative Hemoglobin (g/dl) | 12.4±1.8 | 12.5±1.8 | 12.0±1.5 | |
| Preoperative Hematocrit (%) | 39.1±4.8 | 39.4±4.8 | 37.8±4.7 | |
| Preoperative albumin (g/dl) | 4.2±1.2 | 4.2±0.4 | 4.2±0.4 | 0.280 |
| C-reactive protein (mg/L) | 8.9±7.0 | 8.6±7.1 | 10.1±6.7 | |
| Glasgow prognostic score | ||||
| GPS=0 | 473 (66.4) | 417 (70.6) | 56 (46.3) | |
| GPS≥1 | 239 (33.6) | 174 (29.4) | 65 (53.7) | |
| Intensive Care Unit stay (days) | 3.7±2.8 | 3.62±2.80 | 3.76±3.05 | 0.628 |
| In-hospital stay (days) | 6.8±4.2 | 6.8±4.0 | 6.7±4.7 | 0.893 |
| Ejection fraction, (%) | 50.9±8.7 | 51.2±8.7 | 49.2±8.7 | |
| Left atrial diameter (mm) | 35.8±4.1 | 36.6±4.8 | 35.6±3.9 | 0.12 |
| Mortality, n (%) | ||||
| 30-day | 40 (5.6) | 25 (4.2) | 15 (12.4) | |
| 1-year | 76 (10.7) | 42 (7.1) | 34 (28.1) | |
| Postoperative stroke, n (%) | 26 (3.7) | 3 (0.5) | 23 (19) | |
| POAF – post pperative atrial fibrillation; NYHA – New York Heart Association; EuroSCORE – European System for Cardiac Operative Risk Evaluation, ACEI/ARB – angiotensin converting enzyme/angiotensin receptor blocker, TSH – thyroid stimulating hormone; HbA1c – glycosylated albumin; GPS – Glasgow prognostic score. | ||||